Long-term outcome and prospective validation of NIH
response criteria in 39 patients receiving imatinib for
steroid-refractory chronic GVHD
by Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Nicola Mordini, Roberta
Fedele, Carmine Selleri, Francesco Onida, Francesca Patriarca, Enzo Pavone, Silvia
Svegliati, Armando Gabrielli, Paola Bresciani, Roberta Nuccorini, Sara Pascale,
Sabrina Coluzzi, Fabrizio Pane, Antonella Poloni, Jacopo Olivieri, Pietro Leoni, and
Andrea Bacigalupo
Blood
Volume 122(25):4111-4118
December 12, 2013
©2013 by American Society of Hematology
Individual organ severity scoring within global severity categories.
Attilio Olivieri et al. Blood 2013;122:4111-4118
©2013 by American Society of Hematology
Survival outcomes.
Attilio Olivieri et al. Blood 2013;122:4111-4118
©2013 by American Society of Hematology
Thirty-six of the 39 patients receiving imatinib were alive at 6 months and were included in a
landmark analysis for overall survival (OS) according to response status at 6 months.
Attilio Olivieri et al. Blood 2013;122:4111-4118
©2013 by American Society of Hematology
Mean change in the ROS stimulatory index (ROI) of cGVHD Igs before and after imatinib
treatment according to response status (Center Response).
Attilio Olivieri et al. Blood 2013;122:4111-4118
©2013 by American Society of Hematology